Justine Ceusters

RevaTis and the University of Liège have developed and patented a specific procedure for the collection, production, and storage of autologous muscle-derived mesenchymal stem cells (MdMSC) for immediate therapeutic use or storage for further processing. RevaTis technology is minimally invasive and offers benefits for generating a large number of autologous stem cells.